MEDIA ALERT - Delivering On Our Public Health Commitment: An Update on A (H1N1) Vaccine Supply and Safety
MEDIA ALERT - Delivering On Our Public Health Commitment: An Update on A
(H1N1) Vaccine Supply and Safety
Sanofi-aventis CEO and Sanofi Pasteur CEO Live Via Webcast
WHAT Sanofi-aventis CEO Chris Viehbacher and Sanofi Pasteur
President & CEO Wayne Pisano will discuss how the company is
meeting the challenges of manufacturing A (H1N1) vaccine.
David Greenberg, M.D., Senior Director, Scientific and Medical
Affairs, Sanofi Pasteur, will provide new data from adult and
pediatric clinical trials of the U.S. licensed Influenza A
(H1N1) 2009 Monovalent Vaccine.
WHY Sanofi Pasteur, the largest company in the world devoted
entirely to vaccines -- and the only company producing an
inactivated influenza vaccine at a manufacturing facility
located in the United States -- has worked closely with the
U.S. Department of Health and Human Services and other public
health agencies to develop and produce a safe A (H1N1) vaccine
that provides a robust immune response. Sanofi Pasteur's U.S.
facility has been operating 24 hours a day, seven days a week
to produce A (H1N1) vaccine.
WHEN 2:30 p.m. ET Wednesday, November 11, 2009
HOW To participate in this Webcast briefing, click on the following
link to register and for further login instructions:
http://www.visualwebcaster.com/event.asp?id=63928
Please Note: Participants should be sure to run a system check
when registering to confirm system compatibility. To perform
this check, click the link below the registration form.
CONTACT For additional information:
Freeman Miller
Burson-Marsteller on behalf of Sanofi Pasteur
212-614-4216
Freeman.miller@bm.com
/PRNewswire -- Nov. 10/
SOURCE Sanofi Pasteur









